Tracking the Evolution of Non-Small-Cell Lung Cancer
- PMID: 28445112
- DOI: 10.1056/NEJMoa1616288
Tracking the Evolution of Non-Small-Cell Lung Cancer
Abstract
Background: Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of driver events and evolutionary processes in early-stage NSCLC.
Methods: In this prospective cohort study, we performed multiregion whole-exome sequencing on 100 early-stage NSCLC tumors that had been resected before systemic therapy. We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between intratumor heterogeneity and recurrence-free survival.
Results: We observed widespread intratumor heterogeneity for both somatic copy-number alterations and mutations. Driver mutations in EGFR, MET, BRAF, and TP53 were almost always clonal. However, heterogeneous driver alterations that occurred later in evolution were found in more than 75% of the tumors and were common in PIK3CA and NF1 and in genes that are involved in chromatin modification and DNA damage response and repair. Genome doubling and ongoing dynamic chromosomal instability were associated with intratumor heterogeneity and resulted in parallel evolution of driver somatic copy-number alterations, including amplifications in CDK4, FOXA1, and BCL11A. Elevated copy-number heterogeneity was associated with an increased risk of recurrence or death (hazard ratio, 4.9; P=4.4×10-4), which remained significant in multivariate analysis.
Conclusions: Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor. (Funded by Cancer Research UK and others; TRACERx ClinicalTrials.gov number, NCT01888601 .).
Comment in
-
Liquid-biopsies success highlights power of combining basic and clinical research.Nature. 2017 Apr 26;544(7651):393. doi: 10.1038/544393a. Nature. 2017. PMID: 28447660 No abstract available.
-
Lung cancer: Tracing tumour evolution.Nat Rev Clin Oncol. 2017 Jul;14(7):391. doi: 10.1038/nrclinonc.2017.73. Epub 2017 May 16. Nat Rev Clin Oncol. 2017. PMID: 28508874 No abstract available.
-
Lung Cancer: A Wily Genetic Opponent.Cell. 2017 May 18;169(5):777-779. doi: 10.1016/j.cell.2017.05.001. Cell. 2017. PMID: 28525750
-
Cancer genomics: Tracking cancer evolution.Nat Rev Genet. 2017 Jul;18(7):391. doi: 10.1038/nrg.2017.43. Epub 2017 May 22. Nat Rev Genet. 2017. PMID: 28529335 No abstract available.
-
Seeing the Forest through the Phylogenetic Tree.N Engl J Med. 2017 Jun 1;376(22):2190-2191. doi: 10.1056/NEJMe1704618. N Engl J Med. 2017. PMID: 28564575 No abstract available.
-
TRACERx: Tracking tumor evolution to impact the course of lung cancer.J Thorac Cardiovasc Surg. 2018 Mar;155(3):1199-1202. doi: 10.1016/j.jtcvs.2017.10.134. Epub 2017 Nov 16. J Thorac Cardiovasc Surg. 2018. PMID: 29331175 No abstract available.
-
A richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach.J Thorac Dis. 2018 Mar;10(3):1178-1182. doi: 10.21037/jtd.2018.03.17. J Thorac Dis. 2018. PMID: 29707265 Free PMC article. No abstract available.
MeSH terms
Associated data
Grants and funding
- G108/596/MRC_/Medical Research Council/United Kingdom
- 15951/CRUK_/Cancer Research UK/United Kingdom
- 23896/CRUK_/Cancer Research UK/United Kingdom
- 22246/CRUK_/Cancer Research UK/United Kingdom
- 18892/CRUK_/Cancer Research UK/United Kingdom
- 20274/CRUK_/Cancer Research UK/United Kingdom
- 20465/CRUK_/Cancer Research UK/United Kingdom
- 17891/CRUK_/Cancer Research UK/United Kingdom
- 21999/CRUK_/Cancer Research UK/United Kingdom
- 22795/CRUK_/Cancer Research UK/United Kingdom
- 20466/CRUK_/Cancer Research UK/United Kingdom
- 18176/CRUK_/Cancer Research UK/United Kingdom
- MC_UP_1203/1/MRC_/Medical Research Council/United Kingdom
- 17786/CRUK_/Cancer Research UK/United Kingdom
- 20276/CRUK_/Cancer Research UK/United Kingdom
- 20613/CRUK_/Cancer Research UK/United Kingdom
- 20265/CRUK_/Cancer Research UK/United Kingdom
- 20275/CRUK_/Cancer Research UK/United Kingdom
- 19278/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous